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See Article, pages 990–998In this issue of the Journal, Robotin et al. [1] describe
a decision analysis looking at the cost eﬃcacy of treating
patients with hepatitis B to prevent the development of
hepatocellular carcinoma (HCC). They conclude that
treating patients with active hepatitis B is a cost-eﬀective
way of preventing HCC. As with all decision analysis
models, the devil is in the details and before accepting
that the model reﬂects real life, it is important to exam-
ine the design of the model and the assumptions
required to run the model. First, the population that
was chosen was the Asian population with chronic hep-
atitis B infection because in Australia (and probably in
North America), chronic hepatitis B disproportionately
aﬀects immigrants from Asia. Second, they compared
three strategies. The ‘‘control” strategy or ‘‘low uptake”
strategy was applied to patients with low viral loads
<20,000 IU/mL for those under age 50, and <2000 IU/
mL for those over age 50, who were managed only by
blood testing with no HCC surveillance. The alternate
therapy group patients had higher viral loads. If the
ALT was less than 1.5 the upper limit of normal no
treatment was oﬀered, but patients underwent HCC sur-
veillance. Finally, if the ALT was >1.5 the upper limit
of normal, patients were all treated with entecavir and
underwent HCC surveillance.0168-8278 2009 European Association for the Study of the Liver. Publish
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The ‘‘low uptake” strategy unfortunately, still repre-
sents the state of aﬀairs for many patients with hepatitis
B in the Western world, where hepatitis B awareness
among family physicians can be abysmal. Therefore it
is appropriate as a control strategy. The lack of HCC
surveillance in these groups is not consistent with guide-
lines, which indicate that surveillance should be oﬀered
to all Asian males over age 40 and Asian women over
age 50 regardless of viral load or ALT [2], but this does
not reﬂect reality. The current HCC screening guidelines
are too broad, and will probably be reﬁned in future as
more information about HCC risk becomes available. It
may well be that patients whose disease has been inac-
tive for years (as in the low uptake group) do not need
surveillance. The REVEAL study data suggested that
if the viral load was low the risk of HCC was very low
[3]. Therefore this may be a reasonable strategy.
For those with higher viral loads the treatment strat-
egies are slightly diﬀerent than those described in prac-
tice management guidelines. Most practice guidelines
do not discuss age as a consideration in deciding on
treatment, whereas in this analysis, treatment was lim-
ited to patients over age 35, and criteria for starting
therapy changed at age 50. All guidelines agree that
patients with high viral loads and elevated ALT should
be treated [4,5]. There is less unanimity for patients with
lower ALT concentration. Given that the laboratory
ALT upper limit of normal (ULN) is too high, labora-
tory normal ALT becomes an unreliable marker of inac-
tive disease [6,7]. The REVEAL study showed that
patients who were anti-HBe-positive with normal trans-
aminases had a risk of HCC that was not much diﬀerented by Elsevier B.V. Open access under CC BY-NC-ND license.
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minant of the development of HCC was the viral load,
not the ALT [2]. Others have shown that even patients
with ALT below the laboratory ULN are at risk for
HCC [8], and that a relative risk of 60 for HCC remains
in patients who have normal ALT compared to the risk
in the uninfected) [9]. This decision analysis treated
patients with ALT >1.5  ULN diﬀerently from those
with lower ALT. If the ALT <1.5  ULN cohort were
to have been treated, the reduction in HCC incidence
might have been greater. In real life, liver biopsy would
distinguish those with high viral loads who needed treat-
ment from those who did not, but this analysis did not
consider biopsy. If anything, excluding the ALT
<1.5  ULN cohort from treatment under-estimated
the potential treatment eﬀect, so this is a conservative
approach, and therefore acceptable.
All subjects in the high viral load/ALT >1.5  ULN
cohort received treatment. This may be overkill, because
it is not certain that all such patients are at signiﬁcant
risk of HCC. Patients with late reactivation of disease
after many years of inactive infection are probably not
at as high HCC risk as those who have had persistently
active disease during an equivalent period. However,
this is also a conservative strategy because treating
patients not at risk for HCC will increase costs without
an increase in beneﬁt.
Those members of the cohort who required treatment
were treated with entecavir. Using entecavir simpliﬁes
the model because antiviral resistance is not an issue.
Resistance to entecavir at 2 years is about 1% [10].
Presumably similar considerations will apply to tenofo-
vir, an equally potent agent with low resistance rates
[11].
There are a number of other assumptions used in the
model that may not be accurate, for instance, that
HBeAg seroconversion after interferon or antiviral ther-
apy provides durable protection against active hepatitis
in all. However, the major assumption underlying this
analysis that is open to question is whether treatment
of hepatitis B indeed reduces the risk of HCC. There
is so far no direct evidence that this is true. Indirect evi-
dence does suggest that eﬀective treatment will indeed
reduce the HCC incidence. Indeed, the new EASL
guidelines speciﬁcally state that the goal of preventing
cirrhosis and HCC can be achieved [4].
The risk of HCC is proportional to the elevation of
HBV DNA measured years before the onset of HCC.
This has been demonstrated in several separate large-
scale prospective cohort studies [3,12,13]. Since the
relationship between viral load and HCC incidence
forms a ‘‘biological gradient” suggesting a causal rela-
tionship, it is reasonable to assume that if the viral
load can be reduced with treatment the risk of HCC
will also fall. Although the relationship between treat-
ment and HCC risk reduction has not been studiedthere is clear evidence that treatment of hepatitis B
will reduce the overall risk of progression of disease,
both in patients with cirrhosis and in non-cirrhotics
[14,15]. Since the risk of HCC increases with more
advanced disease, presumably the reduction in the risk
of progression of disease also results in a reduction of
risk of developing HCC. Other indirect evidence
includes that in patients who develop antiviral resis-
tance there is an increase in viral load, with exacerba-
tion of disease activity and with an increased risk of
disease progression [16,17], whereas patients who do
not develop antiviral resistance and who continue to
have adequate viral suppression have a much lower
incidence of deterioration. Finally, the concept is bio-
logically plausible. In other viral diseases (HIV, hepa-
titis C) the lower the viral load the less the disease.
Why should this be any diﬀerent in hepatitis B?
Do we still need data from a randomized controlled
trial (RCT) to convince us that the proposition espoused
by Robotin et al. [1] is true, namely that treatment of
hepatitis B reduces HCC risk? In my humble opinion,
there is suﬃcient indirect evidence that this is true, that
we do not need to wait for data from a RCT, which in
any case might never become available. When data from
RCTs are not available, or RCTs are not feasible, deci-
sion analysis is the next best step. In many countries (my
own being a prominent example) publicly funded access
to eﬀective hepatitis B antivirals is restricted, using the
excuse that no survival beneﬁt has yet been shown and
there is a lack of cost eﬃcacy data. This analysis will
hopefully positively inﬂuence acceptance of the use of
potent antivirals for hepatitis B.
Tong et al. [18] have recently demonstrated that if
AALSD guidelines for the treatment of hepatitis B
had been applied to a cohort of patients who eventually
developed HCC only 20–60% would have been candi-
dates for treatment, suggesting that the guidelines issued
by most professional societies are too restrictive. Sec-
ond, even these restrictive guidelines are probably not
being applied often enough by primary care physicians,
given that only 2% of potential candidates in Australia
are being treated (and anecdotally, elsewhere). In addi-
tion, data from the USA indicate that only a minority
of patients with cirrhosis undergo surveillance before
developing HCC [19].
HCC is increasing in incidence in Western countries
as a consequence of the hepatitis C epidemic from the
1950s and 1960s, but also as a result of immigration
from Asian countries increasing the prevalence of hepa-
titis B. Treatment of viral hepatitis B should dramati-
cally reduce the incidence of HCC, but this will only
happen if more patients with hepatitis B are treated.
In turn, this will require a better understanding of hep-
atitis among primary care physicians. Educating pri-
mary care physicians about hepatitis B remains a
challenge.
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